Search

Bispecific antibodies, including bispecific IgG, are emerging as an important new class of antibody therapeutics. As a result, we, as well as others, have developed engineering strategies designed to facilitate the efficient production of bispecific IgG for clinical development. For example, we have extensively used knobs-into-holes (KIH) mutations to facilitate the heterodimerization of antibody heavy chains and more recently Fab mutations to promote cognate heavy/light chain pairing for efficient in vivo assembly of bispecific IgG in single host cells. A panel of related monospecific and bispecific IgG1 antibodies was constructed and assessed for immunogenicity risk by comparison with benchmark antibodies with known low (Avastin and Herceptin) or high (bococizumab and ATR-107) clinical incidence of anti-drug antibodies. Assay methods used include dendritic cell internalization, T cell proliferation, and T cell epitope identification by in silico prediction and MHC-associated peptide proteomics. Data from each method were considered independently and then together for an overall integrated immunogenicity risk assessment. In toto, these data suggest that the KIH mutations and in vitro assembly of half antibodies do not represent a major risk for immunogenicity of bispecific IgG1, nor do the Fab mutations used for efficient in vivo assembly of bispecifics in single host cells. Comparable or slightly higher immunogenicity risk assessment data were obtained for research-grade preparations of trastuzumab and bevacizumab versus Herceptin and Avastin, respectively. These data provide experimental support for the common practice of using research-grade preparations of IgG1 as surrogates for immunogenicity risk assessment of their corresponding pharmaceutical counterparts.

ABSTRACTRabbits produce robust antibody responses and have unique features in their antibody repertoire that make them an attractive alternative to rodents for in vivo discovery. However, the frequent occurrence of a non-canonical disulfide bond between complementarity-determining region (CDR) H1 (C35a) and CDRH2 (C50) is often seen as a liability for therapeutic antibody development, despite limited reports of its effect on antibody binding, function, and stability. Here, we describe the discovery and humanization of a human-mouse cross-reactive anti-programmed cell death (PD-1) monoclonal rabbit antibody, termed h1340.CC, which possesses this non-canonical disulfide bond. Initial removal of the non-canonical disulfide resulted in a loss of PD-1 affinity and cross-reactivity, which led us to explore protein engineering approaches to recover these. First, guided by the sequence of a related clone and the crystal structure of h1340.CC in complex with PD-1, we generated variant h1340.SA.LV with a potency and cross-reactivity similar to h1340.CC, but only partially recovered affinity. Side-by-side developability assessment of both h1340.CC and h1340.SA.LV indicate that they possess similar, favorable properties. Next, and prompted by recent developments in machine learning (ML)-guided protein engineering, we used an unbiased ML- and structure-guided approach to rapidly and efficiently generate a different variant with recovered affinity. Our case study thus indicates that, while the non-canonical inter-CDR disulfide bond found in rabbit antibodies does not necessarily constitute an obstacle to therapeutic antibody development, combining structure- and ML-guided approaches can provide a fast and efficient way to improve antibody properties and remove potential liabilities.

In this work, the effect of cellulose ether (CE), tartaric acid (TA), and polycarboxylate superplasticizer (PCE) on the working performance and mechanical properties of cement-based self-leveling mortar is investigated. According to the orthogonal experiment analysis, TA is identified as the most influential factor affecting the working performance, as indicated by factors such as fluidity, fluidity loss, and viscosity. Upon conducting a comprehensive assessment of the working performance and mechanical properties, the optimal parameters are found to be CE = 0.6 wt.‰, TA = 0.5 wt.‰, and PCE = 2.0 wt.‰. A univariate test highlights that that the working performance improves with the higher TA dosages. Specifically, the exponential reduction of fluidity loss corresponds with an increased TA content. Regarding the mechanical properties of cement-based self-leveling mortar, the compressive and flexural strength exhibit enhancement when the TA dosage remains below 0.4 wt.‰ at the early stage, implying that TA has some influence on the hydration process. Impressively, the 1 d compressive and flexural strengths surpass 7 MPa and 2 MPa, respectively, ensuring the viability of subsequent construction activities. Through an analysis of hydration heat, the effect mechanism of TA on the cement-based self-leveling mortar is derived. The result shows that the addition of TA decelerates the hydration process within the initial 10 h, followed by acceleration in the subsequent 20 h to 30 h. Consequently, this delayed formation of the early hydration product, ettringite, contributes to a more porous structure in the slurry, with low friction leading to a better working performance. A large number of hydration products, such as alumina gel and calcium–silicon–hydrate gel, presented in the hardened paste results in the good mechanical properties at 1 d. This study may lay a foundation for the optimization of the dosage of chemical admixtures in the self-leveling mortar and high-performance cement-based materials, and also impart valuable insights for practical applications extending to the realm of building construction and decoration.

Abstract A soluble melanin pigment produced by Streptomyces sp. ZL-24 was purified and named StrSM. The elemental analysis of StrSM showed it consists of carbon, hydrogen, and oxygen. The spectrum analysis, including ultraviolet–visible absorption spectrum, Fourier-transform infrared spectrum, and pyrolysis–gas chromatography–mass spectrometry, indicated that StrSM might be pyomelanin. High performance liquid chromatography and liquid chromatography–mass spectra analysis of intermediate metabolite showed the presence of homogentisic acid (HGA). Moreover, the enzyme 4-hydroxyphenylpyruvate dioxygenase, involved in HGA biosynthesis, showed high activity during melanin production. Subsequently, a tyrosinase gene (melC2) and hydroxyphenylpyruvate dioxygenase gene double mutant demonstrated StrSM is pyomelanin. In vitro bioactivity assay showed that StrSM had excellent protective capability against SH-SY5Y cell oxidative injury. To our knowledge, the results firstly provide comprehensive data on Streptomyces pyomelanin identification and a promising candidate compound to treat oxidative injury of neurocytes.

Abstract Background One of the mechanisms by which tumors evade immune surveillance is through shedding of the major histocompatibility complex (MHC) class I chain-related protein A and B (MICA/B) from their cell surface. MICA/B are ligands for the activating receptor NKG2D on NK and CD8 T cells. This shedding reduces cell surface levels of MICA/B and impairs NKG2D recognition. Shed MICA/B can also mask NKG2D receptor and is thought to induce NKG2D internalization, further compromising immune surveillance by NK cells. Methods We isolated human primary NK cells from normal donors and tested the suppressive activity of soluble recombinant MICA in vitro. Utilizing a panel of novel anti-MICA antibodies, we further examined the stimulatory activities of anti-MICA antibodies that reversed the suppressive effects of soluble MICA. Results We show that suppressive effects of soluble MICA (sMICA) on NK cell cytolytic activity was not due to the down-regulation of cell surface NKG2D. In the presence of an α3 domain-specific MICA antibody, which did not obstruct NKG2D binding, sMICA-mediated NK cell suppression was completely reversed. Reversal of NK cell inhibition by sMICA was mediated by immune complex formation that agonized NKG2D signaling. Furthermore, this restorative activity was dependent on antibody Fc effector function as the introduction of Fc mutations to abrogate Fc receptor binding failed to reverse sMICA-mediated NK cell suppression. Furthermore, MICA immune complexes preformed with an α3 domain-specific antibody (containing a wild-type Fc) induced IFN-γ and TNF-α secretion by NK cells in the absence of cancer cells, whereas MICA immune complexes preformed with the Fc effectorless antibody failed to induce IFN-γ and TNF-α secretion. Finally, we demonstrated that MICA immune complexes formed with the α3 domain-specific antibody activates NKG2D on NK cells leading to the release of IFN-γ. Conclusions Our results demonstrate that an α3 domain-specific MICA antibody can circumvent sMICA-mediated suppression of NK cell cytolytic activity. Moreover, our data suggest that MICA immune complexes formed with α3-specific antibodies can activate NKG2D receptor and restore NK cell function in a Fc-dependent manner. The clinical utility of α3 domain-specific MICA/B antibodies may hold great promise as a new strategy for cancer immunotherapy.

As a new alternative to antibody-drug conjugates, we generated "ligand-targeting" peptide-drug conjugates (PDCs), which utilize receptor-mediated endocytosis for targeted intracellular drug delivery. The PDC makes a complex with an extracellular ligand and then binds to the receptor on the cell surface to stimulate intracellular uptake via the endocytic pathway. A helix-loop-helix (HLH) peptide was designed as the drug carrier and randomized to give a conformationally constrained peptide library. The phage-displayed library was screened against vascular endothelial growth factor (VEGF) to yield the binding peptide M49, which exhibited strong binding affinity (KD = 0.87 nM). The confocal fluorescence microscopy revealed that peptide M49 formed a ternary complex with VEGF and its receptor, which was then internalized into human umbilical vein endothelial cells (HUVECs) via VEGF receptor-mediated endocytosis. The backbone-cyclized peptide M49K was conjugated with a drug, monomethyl auristatin E, to afford a PDC, which inhibited VEGF-induced HUVEC proliferation. HLH peptides and their PDCs have great potential as a new modality for targeted molecular therapy.

A xylanase-producing strain, identified as Streptomyces sp. T7, was isolated from soil by our lab. The endo-β-1,4-xylanase (xynST7) gene was found in the genome sequence of strain T7, which was cloned and expressed in Escherichia coli. XynST7 belonged to the glycoside hydrolase family 10, with a molecular mass of approximately 47 kDa. The optimum pH and temperature of XynST7 were pH 6.0 and 60 °C, respectively, and it showed wide pH and temperature adaptability and stability, retaining more than half of its enzyme activity between pH 5.0 and 11.0 below 80 °C. XynST7 showed only endo-β-1,4-xylanase activity without cellulase- or β-xylosidase activity, and it showed maximal hydrolysis for corncob xylan in all the test substrates. Then, XynST7 was used for the production of xylo-oligosaccharides (XOSs) by hydrolyzing xylan extracted from raw corncobs. The maximum yield of the XOS was 8.61 ± 0.13 mg/mL using 15 U/mL of XynST7 and 1.5% corncob xylan after 10 h of incubation at 60 °C. The resulting hydrolysate products mainly consisted of xylobiose and xylotriose. These data indicated that XynST7 might by a promising tool for various industrial applications.

Objective:To investigate the effect of plantar pressure training on gait and walking ability in hemiplegic patients.Methods:Sixty hemiplegic patients were randomly allocated into plantar pressure training group (n=30) and rehabilitation treatment group (n=30). The rehabilitation treatment group received rehabilitation training based on Bobath and Motor Relearn Program, the plantar pressure training group received varied erect position stand and walking on the pressure platform, thirty minutes for each course, 5 courses a week for 3 weeks continuously. Frequency of stride, gait cycle, stride length, pace, step deviation, double support phase were measured before and after treatment by GaitWatch. Walking ability was measured by functional ambulation classification (FAC).Results:An increase of frequency of stride, gait cycle, stride length, pace, step deviation, double support phase was investigated in both groups after training (PPP>0.05).Conclusion:Plantar pressure training can improve the patient's walking ability, effectively enhance the gait of hemiplegic patients.